Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIO

Inicio | Investigación e innovación | Programas Científicos | Programa de Investigación Clínica | Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIO

Investigadores

  • Santiago Barrio
  • Lucia Virginia Fernández
  • Miguel Gallardo
  • María Linares

Investigador Clínico I

  • Rosa María Ayala
  • María Calbacho
  • Gonzalo Carreño
  • María Teresa Cedena
  • Francisco Javier De La Serna
  • Carlos Grande
  • Ana Jiménez
  • María Inmaculada Rapado
  • Antonia Rodríguez
  • Ricardo Sánchez

Becarios Post-doctorales

  • Sergio Algar
  • María del Carmen Fiuza
  • Almudena García
  • Alejandra Leivas
  • María Asunción Martín
  • Antonio Valeri
  • María Velasco

Becarios Pre-Doctorales

  • Pedro Aguilar
  • Javier Alcázar
  • Noemí Álvarez
  • Eva Castellano
  • Isabel Cuenca
  • Jessica Encinas
  • Elena Maroto
  • Michael Ochieng
  • María Alejandra Ortiz
  • Alba Rodríguez
  • Laura Sánchez

Técnicos de Laboratorio

  • Paula Calvo
  • Adrián Fernández
  • Vanesa Garrido
  • Alicia Giménez
  • María Luz Morales
  • Laura Moreno
  • Miguel Ángel Navarro
  • Laura Rufián

Haematological malignancies include a myriad of heterogeneous diseases with high frequency, such as non-Hodgkin’s lymphoma, or with high mortality rates, such as multiple myeloma and acute myeloid leukaemia. In the laboratory, we dissect the biology of haematological cancers by investigating: (i) novel diagnosis and prognosis biomarkers; (ii) innovative tools and techniques to identify and monitor the disease; (iii) original therapeutic targets and treatments against haematological malignancies; and (iv) how to decipher the biological processes underlying the diseases and characterise the drivers, oncogenes and tumour suppressors.

The following main lines of research define our laboratory:

  • Role of hnRNP K, a novel driver of lymphoma and leukaemia in tumorigenesis.
  • Molecular fingerprint in clonal evolution, heterogeneity and drug resistance.
  • Liquid biopsy and next-generation sequencing.
  • Immunotherapy: NK-CAR and T-CAR in haematological and paediatric cancers.

Publicaciones

Subir